Atezolizumab

Cat. No.:	HY-P9904
CAS No.:	1380723-44-3
Molecular Weight:	144590.5
Target:	PD-1/PD-L1; Apoptosis; Autophagy
Pathway:	Immunology/Inflammation; Apoptosis; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
In Vitro	Atezolizumab (0, 2.5, 5, 10, 20, and 40 μg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells[1]. Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10 μg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Discov. 2023 Feb 21;9(1):20.
- Sci Adv. 2023 Apr 7;9(14):eade9944.
- Cell Rep. 2022 Feb 8;38(6):110349.
- Inflammation. 2021 Aug;44(4):1441-1451.
- Lab Invest. 2023 Apr 12;100148.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Cha E, et al. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 2015 Jun;42(3):484-7.

[2]. Liu Z, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12(2):164. Published 2021 Feb 8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA